Assyro AI

Purple Book product · Reference 351(a)

Crofab

Crotalidae Polyvalent Immune Fab (Ovine)

351(a)BLA 103788RxLicensed BTG International Inc.

Oct 02, 2000

Approved

Reference 351(a)

License type

Rx

Marketing

None

Listed patents

Crofab (Crotalidae Polyvalent Immune Fab (Ovine)) is BTG International Inc.'s FDA-licensed reference biologic, approved under a 351(a) BLA in 2000. No biosimilars referencing Crofab are listed in the Purple Book yet.

Sourced from the FDA Purple Book · verified Jul 02, 2026

Key dates

  1. Approval

    Approval date of this BLA submission.

    Oct 02, 2000

    26 yr 2 mo ago

  2. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    Oct 02, 2007

    19 yr 1 mo ago

  3. Today

Pharmaceutical detail

Strength

1G

Dosage form

For Injection

Route

Intravenous

Presentation

Single-Dose Vial

Center

CBER

License number

1861

Product number

001

Submission type

Original

Supplement number

0

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. No biosimilars or interchangeables reference it in the Purple Book yet.

Patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Source provenance

Source kind · Advanced Search
Checked Jul 02, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

Change history

  • v6Jul 02, 2026
  • v5Jul 02, 2026
  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Frequently asked questions

Does Crofab have approved biosimilars?

No 351(k) biosimilars or interchangeable biosimilars referencing Crofab are listed in the FDA Purple Book yet.

What is Crofab's BLA number?

Crofab is licensed under BLA 103788, held by BTG International Inc..

When was Crofab approved by the FDA?

Crofab was approved by the FDA on Oct 02, 2000.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.